-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

Benzinga·11/04/2026 12:40:04
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $52 to $54.